HUE040086T2 - Gyûrûs boronsavészter-származékok és terápiás alkalmazásuk - Google Patents

Gyûrûs boronsavészter-származékok és terápiás alkalmazásuk

Info

Publication number
HUE040086T2
HUE040086T2 HUE11816882A HUE11816882A HUE040086T2 HU E040086 T2 HUE040086 T2 HU E040086T2 HU E11816882 A HUE11816882 A HU E11816882A HU E11816882 A HUE11816882 A HU E11816882A HU E040086 T2 HUE040086 T2 HU E040086T2
Authority
HU
Hungary
Prior art keywords
acid ester
boronic acid
ester derivatives
therapeutic uses
cyclic boronic
Prior art date
Application number
HUE11816882A
Other languages
English (en)
Inventor
Gavin Hirst
Raja Reddy
Scott Hecker
Maxim Totrov
David Griffith
Olga Rodny
Michael Dudley
Serge Boyer
Original Assignee
Rempex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45565270&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE040086(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rempex Pharmaceuticals Inc filed Critical Rempex Pharmaceuticals Inc
Publication of HUE040086T2 publication Critical patent/HUE040086T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
HUE11816882A 2010-08-10 2011-08-08 Gyûrûs boronsavészter-származékok és terápiás alkalmazásuk HUE040086T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37229610P 2010-08-10 2010-08-10
US201161488655P 2011-05-20 2011-05-20

Publications (1)

Publication Number Publication Date
HUE040086T2 true HUE040086T2 (hu) 2019-02-28

Family

ID=45565270

Family Applications (4)

Application Number Title Priority Date Filing Date
HUE11816882A HUE040086T2 (hu) 2010-08-10 2011-08-08 Gyûrûs boronsavészter-származékok és terápiás alkalmazásuk
HUE18183968A HUE048859T2 (hu) 2010-08-10 2011-08-08 Gyûrûs bórsavészter származékok, eljárás elõállításukra, és terápiás alkalmazásuk
HUS1900018C HUS1900018I1 (hu) 2010-08-10 2019-03-28 Gyûrûs boronsavészter-származékok és terápiás alkalmazásuk
HUS1900017C HUS1900017I1 (hu) 2010-08-10 2019-03-28 Gyûrûs boronsavészter-származékok és terápiás alkalmazásuk

Family Applications After (3)

Application Number Title Priority Date Filing Date
HUE18183968A HUE048859T2 (hu) 2010-08-10 2011-08-08 Gyûrûs bórsavészter származékok, eljárás elõállításukra, és terápiás alkalmazásuk
HUS1900018C HUS1900018I1 (hu) 2010-08-10 2019-03-28 Gyûrûs boronsavészter-származékok és terápiás alkalmazásuk
HUS1900017C HUS1900017I1 (hu) 2010-08-10 2019-03-28 Gyûrûs boronsavészter-származékok és terápiás alkalmazásuk

Country Status (27)

Country Link
US (10) US8680136B2 (hu)
EP (3) EP3666778B1 (hu)
JP (4) JP6266978B2 (hu)
KR (3) KR102087313B1 (hu)
CN (1) CN103180328B (hu)
AU (1) AU2011289615B2 (hu)
BR (1) BR112013003045B1 (hu)
CA (1) CA2807546C (hu)
CL (1) CL2013000399A1 (hu)
CO (1) CO6680667A2 (hu)
CY (3) CY1123208T1 (hu)
DK (2) DK3412676T3 (hu)
ES (2) ES2789177T3 (hu)
HR (1) HRP20200741T1 (hu)
HU (4) HUE040086T2 (hu)
IL (1) IL224564A (hu)
LT (3) LT3412676T (hu)
MX (1) MX348653B (hu)
MY (1) MY188960A (hu)
NO (2) NO2019013I1 (hu)
NZ (1) NZ607354A (hu)
PL (2) PL3412676T3 (hu)
PT (2) PT2603514T (hu)
RS (1) RS60310B1 (hu)
RU (1) RU2599791C2 (hu)
SG (1) SG187757A1 (hu)
WO (1) WO2012021455A1 (hu)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103180328B (zh) 2010-08-10 2016-10-26 莱姆派克斯制药公司 环硼酸酯衍生物及其治疗用途
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
WO2013122888A2 (en) * 2012-02-15 2013-08-22 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
US9505728B2 (en) 2012-03-09 2016-11-29 Inception 2, Inc. Triazolone compounds and uses thereof
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US20150238473A1 (en) 2012-09-27 2015-08-27 University Of Rochester Methods and compositions for treating infection
US9422314B2 (en) 2012-12-07 2016-08-23 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
AU2013363398B2 (en) 2012-12-20 2017-06-01 Tempest Therapeutics, Inc. Triazolone compounds and uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2894892A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EA201591003A1 (ru) 2013-01-04 2015-12-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
CN105101970B (zh) 2013-01-10 2018-11-20 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP2991648A4 (en) * 2013-05-03 2017-01-18 Microbiotix, Inc. Antimicrobial potentiators
EA201690230A1 (ru) 2013-09-06 2016-07-29 Инсепшн 2, Инк. Соединения триазолона и их применения
WO2015171398A1 (en) 2014-05-05 2015-11-12 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
HUE046836T2 (hu) 2014-05-05 2020-03-30 Rempex Pharmaceuticals Inc Boronát sók szintézise és alkalmazásuk
AU2015264418A1 (en) 2014-05-19 2016-11-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN106687465B (zh) 2014-06-11 2019-04-16 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
AU2015284307A1 (en) * 2014-07-01 2017-02-02 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016081297A1 (en) * 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN104447610A (zh) * 2014-11-21 2015-03-25 山东金城医药化工股份有限公司 高纯度头孢他啶侧链酸的制备方法
US10364257B2 (en) 2014-12-19 2019-07-30 Rempex Pharmaceuticals, Inc. Apparatus and continuous flow process for production of boronic acid derivatives
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
ES2942329T3 (es) 2015-04-24 2023-05-31 Melinta Therapeutics Inc Régimen de dosificación de vaborbactam y meropenem para el tratamiento de infecciones bacterianas en sujetos con función renal reducida
US10399996B2 (en) 2015-09-11 2019-09-03 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
ES2894251T3 (es) * 2016-06-30 2022-02-14 Qpex Biopharma Inc Derivados de ácido borónico y usos terapéuticos de los mismos
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
AU2017382405B2 (en) * 2016-12-22 2021-12-16 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
US20190336475A1 (en) 2017-01-09 2019-11-07 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
JOP20190188A1 (ar) 2017-02-01 2019-08-01 Rempex Pharmaceuticals Inc جهاز وعملية تدفق مستمرة لإنتاج مشتق حمض بورونيك
EP3592362A4 (en) 2017-03-06 2020-09-02 Venatorx Pharmaceuticals, Inc. SOLID FORMS AND COMBINATION COMPOSITIONS WITH A BETA LACTAMASE INHIBITOR AND USES THEREOF
WO2018218190A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2018218154A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
JP7377545B2 (ja) 2017-10-11 2023-11-10 キューペックス バイオファーマ， インコーポレイテッド ボロン酸誘導体およびその合成
JOP20200101A1 (ar) * 2017-11-01 2022-10-30 Melinta Therapeutics Inc تخليق مشتقات إستر بورونات واستخداماتها
CN111039965B (zh) * 2018-10-12 2020-12-01 新发药业有限公司 一种法硼巴坦的简便制备方法
WO2022182993A1 (en) * 2021-02-25 2022-09-01 Ohio State Innovation Foundation Liposomal formulations of boronic acid containing active agents
CN113214302B (zh) * 2021-04-23 2022-06-24 四川大学 一种抑制金属β-内酰胺酶和/或丝氨酸β-内酰胺酶的3-取代五元环状硼酸酯衍生物

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3686398A (en) 1970-07-20 1972-08-22 Chevron Res 10,9-boroxarophenanthrene as fungicides
US4194047A (en) 1975-11-21 1980-03-18 Merck & Co., Inc. Substituted N-methylene derivatives of thienamycin
US4260543A (en) 1978-07-03 1981-04-07 Merck & Co., Inc. Crystalline N-formimidoyl thienamycin
US4409214A (en) 1979-11-19 1983-10-11 Fujisawa Pharmaceutical, Co., Ltd. 7-Acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
US4353807A (en) 1981-03-24 1982-10-12 Mobil Oil Corporation Lubricants and fuels containing boroxarophenanthrene compounds
FR2573070B1 (fr) 1984-11-13 1987-01-30 Rhone Poulenc Sante Procede de preparation de composes carbonyles
FR2574070B1 (fr) 1984-11-30 1987-02-27 Stam Catalyseur de prise de mortiers d'anhydrite projetes a la lance, a resistance amelioree a un stockage a temperature et humidite elevees, et utilisation d'un tel catalyseur
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US4822786A (en) 1986-07-01 1989-04-18 Kaken Pharmaceutical Co., Ltd. Cephalosporin compounds, and antibacterial agents
ZA893284B (en) 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies
US5442100A (en) 1992-08-14 1995-08-15 The Procter & Gamble Company β-aminoalkyl and β-N-peptidylaminoalkyl boronic acids
US5888998A (en) 1997-04-24 1999-03-30 Synphar Laboratories, Inc. 2-oxo-1-azetidine sulfonic acid derivatives as potent β-lactamase inhibitors
WO1998056392A1 (en) 1997-06-13 1998-12-17 Northwestern University INHIBITORS OF β-LACTAMASES AND USES THEREFOR
US6184363B1 (en) 1997-06-13 2001-02-06 Northwestern University Inhibitors of β-lactamases and uses therefor
WO2000035905A1 (en) 1998-12-16 2000-06-22 Northwestern University INHIBITORS OF β-LACTAMASES AND USES THEREFOR
AU3124300A (en) 1998-12-16 2000-07-03 Northwestern University Inhibitors of beta-lactamases and uses therefor
WO2001023374A1 (en) 1999-09-25 2001-04-05 Smithkline Beecham P.L.C. Piperazine derivatives as 5-ht1b antagonists
CA2388077A1 (en) 1999-10-28 2001-05-03 James M. Balkovec Novel succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections
AU2001292732A1 (en) 2000-09-12 2002-03-26 Larry C. Blasczcak Beta-lactam analogs and uses therefor
SK2462003A3 (en) 2000-09-14 2003-09-11 Pantherix Ltd 3-(Heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents
US6586615B1 (en) 2001-01-10 2003-07-01 Bristol-Myers Squibb Company α-aminoboronic acids prepared by novel synthetic methods
DE10118698A1 (de) 2001-04-17 2002-11-07 Jerini Ag Verfahren zur Immobilisierung und damit hergestellte Anordnungen von Verbindungen auf einer planaren Oberfläche
AU2002360732A1 (en) 2001-12-26 2003-07-24 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
JP2003229277A (ja) 2002-02-04 2003-08-15 Matsushita Electric Ind Co Ltd 発光素子材料およびそれを用いた発光素子並びに装置
AUPS065102A0 (en) 2002-02-20 2002-03-14 Unisearch Limited Fluorous acetalation
US7176227B2 (en) 2002-09-11 2007-02-13 Kureha Corporation Amine compounds and use thereof
US8012603B2 (en) 2002-10-30 2011-09-06 Sumitomo Chemical Company, Limited Polymer compound and polymer light-emitting device using the same
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
US7271186B1 (en) 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
AU2003300358A1 (en) 2002-12-20 2004-07-22 Migenix Corp. Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto
TW200418791A (en) 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
JP4233365B2 (ja) 2003-03-25 2009-03-04 三井化学株式会社 アザジオール錯体化合物、及び該化合物を用いる光記録媒体
US7842941B2 (en) 2003-10-06 2010-11-30 Sumitomo Chemical Company, Limited Aromatic compound
WO2005035532A1 (en) 2003-10-10 2005-04-21 Pfizer Products Inc. Substituted 2h-[1,2,4]triazolo[4,3-a]pyrazines as gsk-3 inhibitors
EP1997533B8 (en) 2003-11-12 2014-10-29 Sino-Med International Alliance, Inc. Heterocyclic boronic acid compounds, dipeptidyl peptidase IV inhibitors
TW200600494A (en) 2004-03-08 2006-01-01 Chugai Pharmaceutical Co Ltd Bisphenyl compounds useful as vitamin d3 receptor agonists
US20060019116A1 (en) 2004-07-22 2006-01-26 Eastman Kodak Company White electroluminescent device with anthracene derivative host
TW200618820A (en) 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
US20060178357A1 (en) 2005-02-10 2006-08-10 Buynak John D Chphalosporin-derived mercaptans as inhibitors of serine and metallo-beta-lactamases
NZ560448A (en) * 2005-02-16 2009-08-28 Anacor Pharmaceuticals Inc Boron-containing small molecules
TWI353981B (en) 2005-02-22 2011-12-11 Teva Pharma Preparation of rosuvastatin
US9184428B2 (en) 2005-03-15 2015-11-10 Uchicago Argonne Llc Non-aqueous electrolytes for lithium ion batteries
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
TW200734311A (en) 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
DK2484680T3 (da) 2005-12-07 2013-09-08 Basilea Pharmaceutica Ag Nyttige kombinationer af monolactam-antibiotika med beta-lactamase-inhibitorer
DK1988779T5 (en) 2006-02-16 2016-10-10 Anacor Pharmaceuticals Inc SMALL boron MOLECULES AS ANTI-INFLAMMATORY AGENTS
US20100009957A1 (en) 2006-09-27 2010-01-14 Blizzard Timothy A Novel inhibitors of beta-lactamase
BRPI0809147A2 (pt) 2007-03-23 2014-08-26 Basilea Pharmaceutica Ag Medicamentos combinados para tratamento de infecções bacterianas
GB0719366D0 (en) * 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
US20100120715A1 (en) * 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
AR069310A1 (es) 2007-11-13 2010-01-13 Protez Pharmaceuticals Inc Inhibidores de beta- lactamasa
ES2533826T3 (es) 2008-01-18 2015-04-15 Merck Sharp & Dohme Corp. Inhibidores de beta-lactamasa
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
US20100256092A1 (en) 2008-05-12 2010-10-07 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2009139834A1 (en) 2008-05-13 2009-11-19 Poniard Pharmaceuticals, Inc. Bioactive compounds for treatment of cancer and neurodegenerative diseases
MA32977B1 (fr) * 2008-12-17 2012-01-02 Anacor Pharmaceuticals Inc Formes polymorphiques du (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo(c(1,2)oxaborol-1-ol
US20120046242A1 (en) 2008-12-24 2012-02-23 Massachusetts Institute Of Technology Molecular activators of the wnt/beta-catenin pathway
WO2010097675A1 (en) 2009-02-27 2010-09-02 Dhanuka Laboratories Ltd. An improved preparation process for cefpodoxime proxetil
US20100292185A1 (en) 2009-05-12 2010-11-18 Burns Christopher J Beta-lactamase inhibitors
WO2010144338A1 (en) 2009-06-08 2010-12-16 Abraxis Bioscience, Llc Triazine derivatives and their therapeutical applications
EP2458995A1 (en) 2009-07-28 2012-06-06 Anacor Pharmaceuticals, Inc. Trisubstituted boron-containing molecules
WO2011103686A1 (en) 2010-02-26 2011-09-01 Viswanatha , Sundaramma CEPHALOSPORIN DERIVATIVES USEFUL AS β-LACTAMASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF
CN102892291A (zh) 2010-03-31 2013-01-23 米伦纽姆医药公司 1-氨基-2-环丙基乙硼酸衍生物
US20110288063A1 (en) 2010-05-19 2011-11-24 Naeja Pharmaceutical Inc. Novel fused bridged bicyclic heteroaryl substituted 6-alkylidene penems as potent beta-lactamase inhibitors
JP5603487B2 (ja) 2010-06-10 2014-10-08 テクニオン リサーチ アンド ディベラップメント ファウンデイション リミテッド ヨウ化物の調製のためのプロセス
CN103180328B (zh) 2010-08-10 2016-10-26 莱姆派克斯制药公司 环硼酸酯衍生物及其治疗用途
RS54750B1 (sr) 2010-10-26 2016-10-31 Mars Inc Borati kao inhibitori arginaze
AU2011329486A1 (en) 2010-11-18 2013-04-18 Glaxo Group Limited Compounds
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
EP2508506A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Preparation of sitagliptin intermediates
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
WO2013053372A1 (en) 2011-10-13 2013-04-18 Therabor Pharmaceuticals Boronic acid inhibitors of beta-lactamases
WO2013056163A1 (en) 2011-10-14 2013-04-18 The Regents Of The University Of California Beta-lactamase inhibitors
BR112014015363A2 (pt) 2011-12-22 2017-06-13 Ares Trading Sa derivados de ácido alfa-amino borônico, inibidores de imunoproteassoma seletivos
WO2013104897A1 (en) 2012-01-09 2013-07-18 University of Tromsø Therapeutic boron-containing compounds
EP2615080A1 (en) 2012-01-12 2013-07-17 LEK Pharmaceuticals d.d. Preparation of Optically Pure ß-Amino Acid Type Active Pharmaceutical Ingredients and Intermediates thereof
WO2013122888A2 (en) 2012-02-15 2013-08-22 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US9422314B2 (en) 2012-12-07 2016-08-23 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CA2894892A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EA201591003A1 (ru) 2013-01-04 2015-12-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
US8999885B2 (en) 2013-01-09 2015-04-07 General Electric Company Methods of activating charcoal resulting from biomass gasification
CN105101970B (zh) 2013-01-10 2018-11-20 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN105283439B (zh) 2013-03-15 2018-02-02 英特瑞克斯顿股份有限公司 含硼的二酰基肼类化合物
HUE046836T2 (hu) 2014-05-05 2020-03-30 Rempex Pharmaceuticals Inc Boronát sók szintézise és alkalmazásuk
WO2015171398A1 (en) 2014-05-05 2015-11-12 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
AU2015264418A1 (en) 2014-05-19 2016-11-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN106687465B (zh) 2014-06-11 2019-04-16 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
US9511142B2 (en) * 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
AU2015284307A1 (en) 2014-07-01 2017-02-02 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016065282A1 (en) 2014-10-24 2016-04-28 The Regents Of The University Of Michigan Nasal formulation, nasal kit, and method for enhancing nasal nitric oxide (no) levels
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
ES2942329T3 (es) 2015-04-24 2023-05-31 Melinta Therapeutics Inc Régimen de dosificación de vaborbactam y meropenem para el tratamiento de infecciones bacterianas en sujetos con función renal reducida
ES2894251T3 (es) 2016-06-30 2022-02-14 Qpex Biopharma Inc Derivados de ácido borónico y usos terapéuticos de los mismos

Also Published As

Publication number Publication date
KR102087313B1 (ko) 2020-03-11
CY1123208T1 (el) 2020-11-25
US20160220591A1 (en) 2016-08-04
WO2012021455A1 (en) 2012-02-16
NZ607354A (en) 2015-01-30
US20230277571A1 (en) 2023-09-07
BR112013003045A2 (pt) 2016-06-14
JP6854861B2 (ja) 2021-04-07
US11090319B2 (en) 2021-08-17
US8680136B2 (en) 2014-03-25
EP2603514A1 (en) 2013-06-19
CY2020019I1 (el) 2020-11-25
US20180207183A1 (en) 2018-07-26
ES2789177T3 (es) 2020-10-26
KR101987091B1 (ko) 2019-06-10
PT3412676T (pt) 2020-05-19
CL2013000399A1 (es) 2013-08-23
LT3412676T (lt) 2020-07-27
US9694025B2 (en) 2017-07-04
JP2020002178A (ja) 2020-01-09
MX348653B (es) 2017-06-21
LTC3412676DI2 (lt) 2022-05-10
DK3412676T3 (da) 2020-05-04
KR102205755B1 (ko) 2021-01-22
HUE048859T2 (hu) 2020-08-28
HUS1900017I1 (hu) 2019-05-28
PT2603514T (pt) 2018-11-09
EP2603514B1 (en) 2018-07-18
DK2603514T3 (en) 2018-10-29
US20190076449A1 (en) 2019-03-14
CY2020019I2 (el) 2020-11-25
US20120040932A1 (en) 2012-02-16
EP3666778B1 (en) 2021-11-10
MY188960A (en) 2022-01-14
US20200222434A1 (en) 2020-07-16
US20180071325A1 (en) 2018-03-15
IL224564A (en) 2017-02-28
JP2021073212A (ja) 2021-05-13
US9296763B2 (en) 2016-03-29
PL2603514T3 (pl) 2019-04-30
AU2011289615B2 (en) 2015-05-07
US10183034B2 (en) 2019-01-22
BR112013003045B1 (pt) 2021-08-31
RU2599791C2 (ru) 2016-10-20
AU2011289615A1 (en) 2013-03-21
CA2807546A1 (en) 2012-02-16
CO6680667A2 (es) 2013-05-31
EP3666778A1 (en) 2020-06-17
RS60310B1 (sr) 2020-07-31
US20220125813A1 (en) 2022-04-28
CA2807546C (en) 2022-08-23
NO2019014I1 (no) 2019-03-28
KR20130099923A (ko) 2013-09-06
LTC3412676I2 (lt) 2022-09-12
RU2013104951A (ru) 2014-09-20
US10004758B2 (en) 2018-06-26
NO2019013I1 (no) 2019-03-28
US20130345172A1 (en) 2013-12-26
JP2013535502A (ja) 2013-09-12
KR20190066084A (ko) 2019-06-12
KR20200028043A (ko) 2020-03-13
PL3412676T3 (pl) 2021-04-06
CN103180328B (zh) 2016-10-26
HUS1900018I1 (hu) 2019-05-28
US20180214465A1 (en) 2018-08-02
CY2020020I2 (el) 2020-11-25
US10639318B2 (en) 2020-05-05
LTPA2020521I1 (lt) 2020-08-10
ES2691468T3 (es) 2018-11-27
JP6602742B2 (ja) 2019-11-06
MX2013001517A (es) 2013-04-29
JP6266978B2 (ja) 2018-01-24
SG187757A1 (en) 2013-03-28
LTPA2020519I1 (lt) 2020-08-10
US11684629B2 (en) 2023-06-27
US10172874B2 (en) 2019-01-08
JP2017052794A (ja) 2017-03-16
CN103180328A (zh) 2013-06-26
EP2603514A4 (en) 2014-10-29
EP3412676B1 (en) 2020-02-12
JP7227282B2 (ja) 2023-02-21
CY2020020I1 (el) 2020-11-25
HRP20200741T1 (hr) 2020-10-16
EP3412676A1 (en) 2018-12-12

Similar Documents

Publication Publication Date Title
HUS1900017I1 (hu) Gyûrûs boronsavészter-származékok és terápiás alkalmazásuk
HK1192879A1 (zh) 取代的 -苄基環烷基羧酸及其用途
EP2542086A4 (en) COMPOUNDS AND ITS THERAPEUTIC USE
GB201010193D0 (en) Medicinal use
IL223153A0 (en) Compositions comprising acid and derivatives thereof and uses thereof
ZA201204414B (en) Oxygen-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
HK1192559A1 (en) 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals 3--
GB201121476D0 (en) Novel pharmaceutical formulation
EP2636666A4 (en) TRANS-2 DECENTRIC ACID DERIVATIVES AND MEDICAMENTS CONTAINING THEREOF
PT2565182T (pt) Novo derivado de amida e a sua utilização como medicamento
EP2864345A4 (en) NUCLEIC ACID PARTICLE CONJUGATES AND THERAPEUTIC APPLICATIONS THEREOF
PL2648715T3 (pl) Mieszaniny karnozyny-kwasu hialuronowego i ich zastosowanie
IL223707A0 (en) N-hydroxyformamide derivative and medicament containing same
EP2650292A4 (en) THIAZOLAMINE DERIVATIVE AND ITS PHARMACEUTICAL APPLICATIONS FOR SMALL RNA VIRAL INFECTIONS
ZA201205684B (en) Ester compound and use thereof
SI3412676T1 (sl) Ciklični derivati estra borove kisline, postopek za njihovo pripravo in njihove terapevtske uporabe
IL214785A0 (en) Dihydrolipoic acid derivatives comprising nitric oxide and therapeutic uses thereof
EP2657236A4 (en) NEW 2-ALKYNYL-N9-PROPARGYLADENINE AND ITS MEDICAL USE
HK1169392A1 (en) Method to prepare 3-acetylisoquinoline and derivatives thereof 3-
GB201018773D0 (en) Topical pharmaceutical formulation
AU2010904801A0 (en) Seleno-Compounds and Therapeutic Uses Thereof